The  global levetiracetam market is anticipated to grow at a significant CAGR during the forecast period. Levetiracetam is a medication that is sold under the brand name Keppra among others and is used to treat epilepsy. According to the World Health Organization (WHO), in 2020, epilepsy is one of the most common neurological diseases globally with around 50 million people diagnosed with it. Additionally, almost 80% of people with epilepsy live in low and middle-income countries and up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. However, the risk of mortality is three times higher in people with epilepsy than in the general populace. Hence the rising prevalence of epilepsy is driving the demand for levetiracetam which in turn is boosting the market growth. 

This medicine is used for partial-onset, myoclonic, or tonic-clonic seizures. It is consumed by mouth as an immediate or extended-release formulation or by injecting directly into a vein. The major factor for the growth of the market is the rising prevalence of epilepsy.  Levetiracetam has numerous benefits such as being affordable, and easy to use. Additionally, the development in formulation techniques to more concentration levels has contributed to the growing demand for the drug. It belongs to a bunch of a group of medications called antiepileptic drugs. It comes under the oral tablet and liquid. 

Impact of COVID-19 on Global Levetiracetam Market

In the COVID-19 situation,the disease has spread to almost every country across the globe with the world health organization declaring public health emergency. The COVID-19 pandemic has made negative impact on the growth of the global levetiracetam  market.  The halt in treatment of several other disorders apart from COVID-19 has lowered the demand for this drug in 2020. 

Segmental Outlook 

The global levetiracetam market is segmented based on form and application. Based on the Form, the market is segmented into tablet, syrup, and injection. Based on the application, the market is sub-segmented into myoclonic treatment and tonic-clonic seizures treatment. The above-mentioned segments can be customized as per the requirements. Among these, the tonic-clonic seizure treatment segment is anticipated to propel the growth of the market over the forecast period, owing to the rising inclination of the pateints towards adoption of levetiracetum fot the treatment of tonic-clonic seizures. 

Global Levetiracetam Market Share by Application,2021(%)

The Tonic-clonic seizures Treatment Segment is Anticipated to Hold a Prominent Share in the Global Levetiracetam Market

Tonic-clonic seizures treatment is anticipated to hold the largest share in the market owing to its convenience. Most people manage seizures through medication. Additionally, US Food and drug administration are approving many medications for the treatment and it is including Carbamazepine, Lamotrigine (Lamictal, Lamictal ODT, so on). The seizures are last between one and three minutes and any other seizures is lasting longer than five minutes. After using these seizures feel sore and headache, tired and unwell. The difference between the tonic and clonic is affected by the muscles. The tonic seizures cause a stiffening of muscles and clonic is characterized by twitching. For instance, in June 2021, anti-seizure medications are referred to as anticonvulsants. It is often recommended to reduce recurrent seizures. In addition, the common anti-seizure medication used for treating tonic-clonic seizures includes Keppra. 

Regional Outlooks

The global levetiracetam market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. The North American regional levetiracetam market is expected to hold a prominent market share during the forecast period due to the presence of several key market players.

Global Levetiracetam Market Growth, by Region 2021-2028

North America is estimated to Hold the Major Share in the Global Levetiracetam Market

North America is anticipated to hold a prominent share in the market due to presence of proper medical reimbursement policies. The growing prevalence of epilepsy, the rising geriatric population, and an increasing number of research and development activities across the region further contributing to the regional market growth. The US dominates this market is due to high healthcare expenditure and developed health infrastructure.

Market Players Outlook

The major companies serving the global levetiracetam include Mylan NV, UCB pharma Ltd., ABA Chem, Laboratories Private Limited,and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers &acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2021, Sagent Pharmaceutical Inc. announced the voluntary nationwide recall of the four lots of Levetiracetam Injection, USP to the user level. Most of the container closure integrity found in reserve sample vials results in a non-sterile product. 

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the globallevetiracetam market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of marketentry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.